Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Quiz|Articles|April 19, 2026
Dermatology Times Spot Test: April 19, 2026
Author(s)Marie Bosslett, Assistant Editor
Listen
0:00 / 0:00
Key Takeaways
- A weekly quiz format is used to reinforce dermatology fundamentals while integrating rapidly evolving clinical and industry developments.
- Current questions prioritize regulatory updates and newly released data, reflecting the pace at which evidence and approvals can reshape therapeutic decision-making.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test.
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest breaking news, including regulatory updates, new data, and more.
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
What age group is targeted in LEO Pharma’s supplemental application for delgocitinib cream?
What makes clascoterone potentially unique in the treatment landscape for androgenetic alopecia?
What proportion of patients with vitiligo did NOT receive treatment in this real-world study?
Advertisement
Related to this article
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
The Value of Precision Medicine in Atopic Dermatitis and Skin Cancers
2
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Day 2 Recap: Fall Clinical 2026
5